The Feasibility of Combining Cost-Effectiveness, Bayesian Meta-Analysis and Meta-Regression Techniques When Evaluating Melanoma Treatment Methods
OncoTargets and Therapy · 2026-08 · Volume 19 · 1-11
DOI: 10.2147/ott.s621292 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift OncoTargets and Therapy, 2026-08. Verfasst von Izabela Gąska und 28 weiteren Autor:innen. Beteiligte Einrichtung: Medical Institute, Jan Grodek State University in Sanok, Sanok, Podkarpackie Voivodeship, 38-500, Poland. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Melanoma treatment encompasses surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy. Despite declining mortality due to therapeutic advances, increasing incidence underscores the growing importance of cost-effectiveness analyses. The integration of cost-effectiveness evaluation with Bayesian meta-analysis and meta-regression may enhance the synthesis of heterogeneous evidence.
Methods
A systematic literature review was conducted to identify studies reporting quality-adjusted life years (QALYs) and direct treatment costs for melanoma in PubMed, MEDLINE, and MEDLINE Ultimate. Bayesian meta-analysis with non-informative priors was applied to derive pooled estimates and quantify uncertainty.
Results
A total of 272 studies were identified, of which only a limited subset met the inclusion criteria. The studies exhibited substantial heterogeneity in treatments, populations, time horizons, perspectives, and costs. Meta-analysis based on the effects provided in one study showed that chemotherapy demonstrated lower effectiveness, as measured by QALYs, compared with treatment sequences such as Anti-PD1 → Bi-TT and Bi-TT → Anti-PD1 in both BRAF-mutated and wild-type populations. Lower costs were associated with chemotherapy, ipilimumab, and Anti-PD1 relative to combination and sequential regimens. Meta-analysis based on the effects provided in another study showed that treatment costs increased with advancing disease stage (≥IIIA) and exhibited greater variability in advanced melanoma.
Conclusion
The combined methodological approach enhances the robustness and comparability of estimates. The observed variability in both clinical effectiveness and costs, across treatment strategies and disease stages, has important implications for healthcare decision-making and resource allocation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Institute, Jan Grodek State University in Sanok, Sanok, Podkarpackie Voivodeship, 38-500, Poland.
- Department of Epidemiology, Maria Sklodowska-Curie National Research Institute of Oncology - Krakow Branch, Krakow, Poland.
- Department of Health Economics, and Insurance, Medical University of Warsaw, Warsaw, Mazowieckie Voivodeship, 00-581, Poland.
- Faculty of Medicine, and Health Sciences, University of Kalisz, Kalisz, Wielkopolskie Voivodeship, 62-800, Poland.
- Department of Family Medicine, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Dolnośląskie Voivodeship, 51-141, Poland.
- Department of Clinical Neurosciences, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Dolnośląskie Voivodeship, 50-376, Poland.
ORCID-Profile: Dorota Charkiewicz, Anna Maria Cybulska, Daria Schneider-Matyka
Zitieren
APA
Gąska, I., Czerw, A., Pajewska, M., Partyka, O., Charkiewicz, D., Kaczmar, E., Sygit, K., Sygit, M., Dziubek, I. T., Wojtyła-Buciora, P., Drobnik, J., Pobrotyn, P., Waśko-Czopnik, D., Sowiński, T., Tejza, K., Grata-Borkowska, U., Strzępek, Ł., Curyło, M., Zawadzka, M., …, & Kozlowski, R. (2026). The Feasibility of Combining Cost-Effectiveness, Bayesian Meta-Analysis and Meta-Regression Techniques When Evaluating Melanoma Treatment Methods. OncoTargets and Therapy, Volume 19, 1-11. https://doi.org/10.2147/ott.s621292
Vancouver
Gąska I, Czerw A, Pajewska M, Partyka O, Charkiewicz D, Kaczmar E, et al. The Feasibility of Combining Cost-Effectiveness, Bayesian Meta-Analysis and Meta-Regression Techniques When Evaluating Melanoma Treatment Methods. OncoTargets and Therapy. 2026;Volume 19:1-11. doi:10.2147/ott.s621292
BibTeX
@article{Gska2026,
author = {Gąska, Izabela and Czerw, Aleksandra and Pajewska, Monika and Partyka, Olga and Charkiewicz, Dorota and Kaczmar, Elżbieta and Sygit, Katarzyna and Sygit, Marian and Dziubek, Ireneusz Teodor and Wojtyła-Buciora, Paulina and Drobnik, Jarosław and Pobrotyn, Piotr and Waśko-Czopnik, Dorota and Sowiński, Tomasz and Tejza, Katarzyna and Grata-Borkowska, Urszula and Strzępek, Łukasz and Curyło, Mateusz and Zawadzka, Magdalena and Grochans, Elżbieta and Cybulska, Anna Maria and Schneider-Matyka, Daria and Rachubińska, Kamila and Bandurska, Ewa and Ciećko, Weronika and Czerw, Natalia and Marczak, Michał and Borzuchowska, Monika and Kozlowski, Remigiusz},
title = {The Feasibility of Combining Cost-Effectiveness, Bayesian Meta-Analysis and Meta-Regression Techniques When Evaluating Melanoma Treatment Methods},
journal = {OncoTargets and Therapy},
year = {2026},
volume = {Volume 19},
pages = {1--11},
doi = {10.2147/ott.s621292}
}
EUVIMED